Physician practices that offer night and weekend hours keep costs down without adversely affecting mortality rates, according to a study in the Annals of Family Medicine.

The study — “Extended Office Hours and Health Care Expenditures: A National Study” — says that “Extended access may thus represent a marker of primary care practices with a cost-conscious approach. This finding may be useful to health administrators and policy makers interested in relatively simple ways of identifying such practices — a seemingly important aim given the health care financing crisis.”

The study ( analyzed nearly 31,000 responses to the Medical Expenditure Panel Surveys (MEPS), finding that patients with access to physicians with extended hours had more than 10 percent lower total expenditures for office visits, ER use, prescription medications, and hospitalizations.

It’s too soon, however, to demand that doctors change their routines, Anthony Jerant, MD, the main author of the study, tells Managed Care. “We think it is premature to recommend, based on this one study, that all physicians consider adding evening and weekend hours.”

Still, the study states that “extended hours may be associated with relatively judicious use of primary health care resources (e.g., more generic medication prescribing, less discretionary testing), with no apparent adverse effects on survival.”

Data were collected from people ages 18–90 who participated in the surveys.

“It’s pooled data for 2000–2008,” says Jerant. “Each individual participant in MEPS is enrolled only for two years.” If a person enrolled in 2000, then 2000 is year one for him, and 2001 is year two. “Since the MEPS survey questions we employed in our study analyses didn’t change from year to year during the 2000–2008 period, we were able to pool data for waves of participants during these years — which dramatically increased the sample size (as opposed to just focusing on one wave) and statistical power to examine our study questions. Such pooling for analyses is common when using data from large surveys like MEPS, when the data collection approach remains the same over a period of years.”

Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.